Clinical reference Biomarker Directory
Back to directory

HGF

Emerging

HGF/MET pathway activation is a key mechanism of resistance to EGFR-targeted lung cancer therapy.

Also known as HGF scatter factor
In plain language

HGF signals through a receptor called MET, and this pathway becoming overactive is a key reason some lung cancers stop responding to certain targeted drugs. Newer drugs specifically targeting this pathway are in active development.

Biomarker & context

Hepatocyte growth factor (HGF) is the ligand for the MET receptor tyrosine kinase, involved in cell growth, motility, and tissue regeneration, with significant relevance to cancer biology.

What it indicates

HGF/MET pathway activation is implicated in resistance to targeted therapies, particularly EGFR inhibitors in lung cancer, where MET amplification is a well-documented resistance mechanism.

Diagnosis & clinical testing

HGF and MET pathway activity are assessed via tumor tissue testing (MET amplification/mutation testing) in treatment-resistance workups, particularly for lung cancer patients progressing on EGFR-targeted therapy.

Guiding treatment

MET inhibitors and HGF-targeted antibodies are active areas of drug development for MET-altered cancers and for overcoming EGFR-inhibitor resistance, representing a genuinely evolving area of precision oncology.

Clinical significance

An active precision oncology drug development target for overcoming treatment resistance.

References
  1. General oncology reference literature on HGF/MET pathway in EGFR-inhibitor resistance in lung cancer.